Platelet lysate obtained via plateletpheresis performed in standing and awake equine donors

Sumner, Scarlett M.; Naskou, Maria C.; Thoresen, Merrilee; Copland, Ian B.; Peroni, John F.

doi:10.1111/trf.14124

Cited by 18 publications

(22 citation statements)

References 30 publications

(41 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…TGF-β seems to be especially important for the synthesis of proteoglycans and collagen type II [ 54 , 55 ] and for the differentiation of MSCs into chondrocytes, a process that has been documented by measuring the chondrogenic-related transcriptional factor Sox9 and mRNA expression of collagen type II [ 56 ]. It is possible that the relatively high concentrations of TGF-β present in ePL [ 26 ] might have been responsible for favoring MSC chondrogenic differentiation.…”

Section: Discussionmentioning

confidence: 99%

“…The preparation of ePL was conducted as previously described [ 26 ]. Briefly, platelet concentrates were obtained following plateletpheresis (COBE Spectra Dual-Needle) performed in five mix-breed horses belonging to the University of Georgia equine blood donors.…”

Section: Methodsmentioning

confidence: 99%

“…Differences in the preparation process of PL such as platelet separation methods (apheresis versus two-step centrifugation), platelet activation (freeze/thaw cycles versus calcium chloride), and removal of platelet fragments, can affect PL growth factor concentrations and therefore influence the proliferative rate and the differentiation capacity of MSCs [ 5 , 24 , 25 ]. We have recently shown that ePL can be safely generated after performing plateletpheresis in awake and standing horses [ 26 ]. Furthermore, our studies suggested that ePL suppresses the release of proinflammatory cytokines from LPS-stimulated equine monocytes and that it can be successfully used as a media supplement for the culture of cells without triggering immune responses [ 27 ].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Platelet lysate as a novel serum-free media supplement for the culture of equine bone marrow-derived mesenchymal stem cells

et al. 2018

Self Cite

View full text Add to dashboard Cite

BackgroundMesenchymal stem cells (MSCs) produced for clinical purposes rely on culture media containing fetal bovine serum (FBS) which is xenogeneic and has the potential to significantly alter the MSC phenotype, rendering these cells immunogenic. As a result of bovine-derived exogenous proteins expressed on the cell surface, MSCs may be recognized by the host immune system as non-self and be rejected. Platelet lysate (PL) may obviate some of these concerns and shows promising results in human medicine as a possible alternative to FBS. Our goal was to evaluate the use of equine platelet lysate (ePL) pooled from donor horses in place of FBS to culture equine MSCs. We hypothesized that ePL, produced following apheresis, will function as the sole media supplement to accelerate the expansion of equine bone marrow-derived MSCs without altering their phenotype and their immunomodulatory capacity.MethodsPlatelet concentrate was obtained via plateletpheresis and ePL were produced via freeze-thaw and centrifugation cycles. Population doublings (PD) and doubling time (DT) of bone marrow-derived MSCs (n = 3) cultured with FBS or ePL media were calculated. Cell viability, immunophenotypic analysis, and trilineage differentiation capacity of MSCs were assessed accordingly. To assess the ability of MSCs to modulate inflammatory responses, E. coli lipopolysaccharide (LPS)-stimulated monocytes were cocultured with MSCs cultured in the two different media formulations, and cell culture supernatants were assayed for the production of tumor necrosis factor (TNF)-α.ResultsOur results showed that MSCs cultured in ePL media exhibited similar proliferation rates (PD and DT) compared with those cultured in FBS at individual time points. MSCs cultured in ePL showed a statistically significant increased viability following a single washing step, expressed similar levels of MSC markers compared to FBS, and were able to differentiate towards the three lineages. Finally, MSCs cultured in ePL efficiently suppressed the release of TNF-α when exposed to LPS-stimulated monocytes similar to those cultured in FBS.ConclusionePL has the potential to be used for the expansion of MSCs before clinical application, avoiding the concerns associated with the use of FBS.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Platelet lysate as a novel serum-free media supplement for the culture of equine bone marrow-derived mesenchymal stem cells

et al. 2018

Self Cite

View full text Add to dashboard Cite

show abstract

“…PL can be prepared in autologous or allogeneic forms, using platelets collected by apheresis or PRP method (Burnouf et al, 2013;Sumner et al, 2017). Autologous prepared PL lacks immune responses (Hemeda et al, 2014) and is used in clinical trials (Shih & Burnouf, 2015).…”

Section: Preparation Of Plmentioning

confidence: 99%

Novel therapeutic approaches in utilizing platelet lysate in regenerative medicine: Are we ready for clinical use?

Zamani

Yaghoubi

Movassaghpour

et al. 2019

Journal Cellular Physiology

View full text Add to dashboard Cite

Hemoderivative materials are used to treat different diseases. These derivatives include platelet‐rich plasma, serum, platelet gel, and platelet lysate (PL). Among them, PL contains more growth factors than the others and its production is inexpensive and easy. PL is one of the proper sources of platelet release factors. It is used in cells growth and proliferation and is a good alternative to fetal bovine serum. In recent years, the clinical use of PL has gained more appeal by scientists. PL is a solution saturated by growth factors, proteins, cytokines, and chemokines and is administered to treat different diseases such as wound healing, bone regeneration, alopecia, oral mucositis, radicular pain, osteoarthritis, and ocular diseases. In addition, it can be used in cell culture for cell therapy and tissue transplantation purposes. Platelet‐derived growth factor, fibroblast growth factor, insulin‐like growth factor, transforming growth factor β, and vascular endothelial growth factor are key PL growth factors playing a major role in cell proliferation, wound healing, and angiogenesis. In this paper, we scrutinized recent advances in using PL and PL‐derived growth factors to treat diseases and in regenerative medicine, and the ability to replace PL with other hemoderivative materials.

show abstract

“…Growth factors and chemokines include transforming growth factor β (TGF-β), brain-derived neurotrophic factor (BDNF), insulin-like growth factor 1 (IGF-1), vascular endothelial growth factor (VEGF), epidermal growth factor (EGF), platelet-derived growth factor AA (PDGF-AA), -AB and -BB, basic fibroblast growth factor (bFGF or FGF-2), bone morphogenetic protein 2,4,6 (BMP-2,-4,-6), hepatocyte growth factor (HGF), connective tissue growth factor (CTGF), chemokine (CXC) ligand12 (SDF-1), CXCL10, CXCL5, CXCL4 (PF4), CXCL3, CXCL2, CXCL1, and inflammatory cytokines such as: interferonγ (IFN-γ), tumor necrosis factorα (TNF-α), granulocyte-macrophage colony-stimulating factor (GM-CSF), granulocyte-colonystimulating factor (G-CSF), interleukin8 (IL-8), IL-7, IL-6, IL-1a, macrophage inflammatory protein 1a (MIP-1a), and MIP-1b. All are involved in differentiation, proliferation, angiogenesis, ulcer closure, and repair [7][8][9][10][11]. Leotot et al (2013), in an animal model, found that the mesenchymal stromal cells seeded on PL, coated with the hydroxyapatite/ b-tricalcium phosphate, enhanced vascularization and bone formation in mice [12].…”

Section: Pl/vancomycin/nano-hydroxyapatite Preparation and Characterimentioning

confidence: 99%

PL/Vancomycin/Nano-hydroxyapatite Sustained-release Material to Treat Infectious Bone Defect

Liu

Wang

Wang³

et al. 2020

Open Life Sciences

View full text Add to dashboard Cite

AbstractObjectiveTo evaluate the therapeutic effect of platelet lysate (PL)/vancomycin/nano-hydroxyapatite sustained-release material on treating staphylococcus aureus-induced infectious bone defects.Methods40 New Zealand white rabbits were inoculated with staphylococcus aureus to construct the chronic tibial infectious bone defect model. After incision, debridement and washing, control group 1 was not given any filling, control group 2 was filled with PL/nano-hydroxyapatite sustained release material, control group 3 was filled with vancomycin/ nano-hydroxyapatite sustained release material, and the treatment group was filled with PL/vancomycin/nano-hydroxyapatite sustained-release material. Afterwards, the drug release profiles were determined in vitro and in vivo. Then, X-rays and bone specimens were used to evaluate the efficacy of the treatments.ResultsTGF-β and PDGF were effectively released for 28 days in vitro. In addition, results of the inhibition zone experiment of the composite material proved that vancomycin had favorable antibacterial activity, which effectively suppressed bacteria for as long as 43 days, thus achieving the sustained-release antibacterial effect. The drug release profiles in vitro also demonstrated that the vancomycin concentration within the lesion region was the highest in composite material, and the infection in experimental rabbits was markedly alleviated. The original backbone deformity regained the normal shape, the normal bone marrow structure began to recover 6 weeks later, and the nano-hydroxyapatite transformed into the trabecula structure. By contrast, the inflammation in the control group still existed, with no obvious new bone formation.ConclusionThe PL/vancomycin/nano-hydroxyapatite sustained-release material effectively treats chronic infectious bone defects.

show abstract

Platelet lysate obtained via plateletpheresis performed in standing and awake equine donors

Cited by 18 publications

References 30 publications

Platelet lysate as a novel serum-free media supplement for the culture of equine bone marrow-derived mesenchymal stem cells

Platelet lysate as a novel serum-free media supplement for the culture of equine bone marrow-derived mesenchymal stem cells

Novel therapeutic approaches in utilizing platelet lysate in regenerative medicine: Are we ready for clinical use?

PL/Vancomycin/Nano-hydroxyapatite Sustained-release Material to Treat Infectious Bone Defect

Contact Info

Product

Resources

About